Colossal Biosciences
Colossal Biosciences raises $120M Series at $800M valuation
Colossal Biosciences: Series Funding Round
Colossal Biosciences has successfully raised $120M in Series funding, reaching a valuation of $800M.
Company Overview
Working on de-extinction of species including mammoths and dodos
Funding Details
The Series round was led by CIA In-Q-Tel, with participation from Breyer Capital.
Company Information
- Headquarters: Austin, TX
- Founded: 2021
- Employees: 100+
- Category: Biotech
Investment
Colossal Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- CIA In-Q-Tel: Verified investor in Series
- Breyer Capital: Verified investor in Series
Company Info
Investors (2)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free